Full-Time
Posted on 10/31/2025
Biopharma protein expression and purification platform
$110k - $150k/yr
Vancouver, WA, USA
Remote
| , , |
AbSci provides biopharma-focused protein expression and biomanufacturing solutions. Its core platform uses a semi-oxidizing cytoplasm and a dual inducible promoter to tightly control protein production, enabling efficient and scalable production of folded, active proteins. A key offering is SoluPure, a chromatography-free purification method that simplifies downstream processing, reducing bottlenecks and costs. Their high-throughput workflow can generate cell lines that produce properly folded proteins in as little as three months, speeding drug development. Compared with traditional systems like CHO mammalian cells, AbSci emphasizes integrating expression and purification with a faster, more cost-effective pipeline and scalable biomanufacturing. The company aims to transform biologics manufacturing by delivering streamlined, high-throughput protein production and purification services to pharmaceutical and biotech customers.
Company Size
51-200
Company Stage
IPO
Headquarters
Vancouver, Washington
Founded
2011
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Company Equity
Employee Stock Purchase Plan
Absci to participate in the 25th Annual Needham Virtual Healthcare Conference. VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference. Absci management is scheduled to participate in a fireside chat on Thursday, April 16th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: investors.absci.com. About Absci Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation(TM) platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201(TM), a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential "best-in-class" therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube. Absci(R) standard character mark, ABS-201(TM), and Integrated Drug Creation(TM) are trademarks and registered trademarks of Absci Corporation. Investor Contact Alexander D.H. Khan Corporate Vice President Head of Investor Relations [email protected]
Absci, a loss-making biotech company, held $144 million in cash as of December 2025, giving it approximately 18 months of runway based on its $94 million annual cash burn. The company's cash burn increased 29% year-on-year, whilst operating revenue fell 38% over the same period. The metrics raise concerns about the company's development trajectory. Absci carries minimal debt, but analysts are closely monitoring its cash position. If the company exhausts its current reserves, it would likely need to raise additional capital through equity issuance or debt financing. The company's ability to secure future funding may be challenged by its declining revenue and increasing burn rate, making its cash management situation particularly important for shareholders to watch.
Absci Corp reported $700,000 in revenue for Q4 2025, with research and development expenses rising to $25.3 million from $18.4 million year-over-year. The company recorded a $5.1 million gain from settling contingent consideration, generating $8.7 million in unrestricted cash. The biotech firm held $144.3 million in cash, cash equivalents and marketable securities as of 31 December 2025, sufficient to fund operations into the first half of 2028. Its lead candidate ABS-201 is advancing in clinical trials for hair loss treatment, with the company expanding into endometriosis as a second indication. Absci demonstrated the first de novo full-length antibody design to zero prior epitopes, showcasing its AI platform capabilities. However, the company faces significant competition and remains heavily reliant on partnerships for its oncology programmes.
Absci Corporation reported a fourth-quarter loss of $0.23 per share, missing the Zacks Consensus Estimate of a $0.16 loss by 40.24%. This compares to a loss of $0.25 per share in the same period last year. The biomedical and genetics company posted revenues of $0.65 million for the quarter ended December 2025, missing estimates by 82.15%. This compares to year-ago revenues of $0.67 million. The company has failed to beat consensus revenue estimates over the past four quarters and has surpassed EPS estimates only once during that period. Absci shares have declined 16.1% since the beginning of the year, compared to the S&P 500's 3.9% decline. The company currently holds a Zacks Rank of 3, indicating shares are expected to perform in line with the market.
Absci Corp is set to report Q4 2025 earnings on 24 March 2026. The consensus estimate projects revenue of $1.10 million and a loss of $0.20 per share for the quarter. For the full year 2025, revenue is expected at $4.92 million with a loss of $0.85 per share. Revenue estimates for 2026 have declined from $26.47 million to $20.33 million over the past 90 days. In the previous quarter, Absci missed revenue expectations by 77%, reporting $0.38 million against estimates of $1.64 million. The stock fell 22% following that announcement. Analysts maintain an average price target of $8.05, suggesting a 171% upside from the current price of $2.97, with an "Outperform" consensus recommendation from nine brokerage firms.